BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27150568)

  • 21. Identification of genetic risk for pancreatic adenocarcinoma.
    Flores K; Dinh K; Rouleau E; Whalen G; Wassef W; LaFemina J
    Cancer Genet; 2015 Nov; 208(11):559-63. PubMed ID: 26481832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?
    Partensky C
    Pancreas; 2013 Jul; 42(5):729-39. PubMed ID: 23648843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
    Steele CW; Oien KA; McKay CJ; Jamieson NB
    Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
    Grochola LF; Müller TH; Bond GL; Taubert H; Udelnow A; Würl P
    Pancreas; 2010 Jan; 39(1):76-80. PubMed ID: 19752772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
    Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK
    Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased risk of gastrointestinal lymphoma in carriers of the 657del5 NBS1 gene mutation.
    Steffen J; Maneva G; Popławska L; Varon R; Mioduszewska O; Sperling K
    Int J Cancer; 2006 Dec; 119(12):2970-3. PubMed ID: 16998789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia.
    Buslov KG; Iyevleva AG; Chekmariova EV; Suspitsin EN; Togo AV; Kuligina ESh; Sokolenko AP; Matsko DE; Turkevich EA; Lazareva YR; Chagunava OL; Bit-Sava EM; Semiglazov VF; Devilee P; Cornelisse C; Hanson KP; Imyanitov EN
    Int J Cancer; 2005 Apr; 114(4):585-9. PubMed ID: 15578693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of genetic variants of ABCB1, APOB, CAV1, and NAMPT on susceptibility to pancreatic ductal adenocarcinoma in Chinese patients.
    Li B; Zhang C; Wang J; Zhang M; Liu C; Chen Z
    Mol Genet Genomic Med; 2020 Jun; 8(6):e1226. PubMed ID: 32243098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies.
    Chrzanowska KH; Piekutowska-Abramczuk D; Popowska E; Gładkowska-Dura M; Małdyk J; Syczewska M; Krajewska-Walasek M; Goryluk-Kozakiewicz B; Bubała H; Gadomski A; Gaworczyk A; Kazanowska B; Kołtan A; Kuźmicz M; Luszawska-Kutrzeba T; Maciejka-Kapuścińska L; Stolarska M; Stefańska K; Sznurkowska K; Wakulińska A; Wieczorek M; Szczepański T; Kowalczyk J
    Int J Cancer; 2006 Mar; 118(5):1269-74. PubMed ID: 16152606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma.
    Pistoni L; Gentiluomo M; Lu Y; López de Maturana E; Hlavac V; Vanella G; Darvasi E; Milanetto AC; Oliverius M; Vashist Y; Di Leo M; Mohelnikova-Duchonova B; Talar-Wojnarowska R; Gheorghe C; Petrone MC; Strobel O; Arcidiacono PG; Vodickova L; Szentesi A; Capurso G; Gajdán L; Malleo G; Theodoropoulos GE; Basso D; Soucek P; Brenner H; Lawlor RT; Morelli L; Ivanauskas A; ; Kauffmann EF; Macauda A; Gazouli M; Archibugi L; Nentwich M; Loveček M; Cavestro GM; Vodicka P; Landi S; Tavano F; Sperti C; Hackert T; Kupcinskas J; Pezzilli R; Andriulli A; Pollina L; Kreivenaite E; Gioffreda D; Jamroziak K; Hegyi P; Izbicki JR; Testoni SGG; Zuppardo RA; Bozzato D; Neoptolemos JP; Malats N; Canzian F; Campa D
    Carcinogenesis; 2021 Aug; 42(8):1037-1045. PubMed ID: 34216462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.
    Aichler M; Seiler C; Tost M; Siveke J; Mazur PK; Da Silva-Buttkus P; Bartsch DK; Langer P; Chiblak S; Dürr A; Höfler H; Klöppel G; Müller-Decker K; Brielmeier M; Esposito I
    J Pathol; 2012 Apr; 226(5):723-34. PubMed ID: 21984419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated genomic, transcriptomic, and RNA-interference analysis of genes in somatic copy number gains in pancreatic ductal adenocarcinoma.
    Samuel N; Sayad A; Wilson G; Lemire M; Brown KR; Muthuswamy L; Hudson TJ; Moffat J
    Pancreas; 2013 Aug; 42(6):1016-26. PubMed ID: 23851435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
    Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
    Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
    Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
    J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
    Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
    PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
    Lener MR; Scott RJ; Kluźniak W; Baszuk P; Cybulski C; Wiechowska-Kozłowska A; Huzarski T; Byrski T; Kładny J; Pietrzak S; Soluch A; Jakubowska A; Lubiński J
    Int J Cancer; 2016 Aug; 139(3):601-6. PubMed ID: 27038244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
    Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?
    Connor AA; Gallinger S
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):683-694. PubMed ID: 28460572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma.
    Chen DT; Davis-Yadley AH; Huang PY; Husain K; Centeno BA; Permuth-Wey J; Pimiento JM; Malafa M
    PLoS One; 2015; 10(8):e0133562. PubMed ID: 26247463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.